The Cheap Selank Vial Is Not a Bargain. It’s a Bet You Can’t Insure.

Last updated June 2026.

Selank is not an FDA-approved drug in the United States. Every clinical figure below links to its primary source.

Here is the unfashionable claim I want to defend: price is the least useful number on a Selank listing, and most buyers weight it first. I get why. A dollar figure is concrete, it’s right there next to the “add to cart” button, and everything else, oversight, testing, legal structure, requires actual reading. But if you rank sellers by sticker price you will consistently pick the option with the worst recourse when something goes wrong, and something going wrong is exactly the scenario a research-stage peptide should make you plan for.

So I didn’t rank on price. I built a scorecard around a blunter question: if the vial is contaminated, mislabeled, or just wrong, who do you call? Five criteria, twenty points apiece, one hundred total. Oversight and dispensing (whether a clinician and a licensed pharmacy stand between you and the product) carry forty of those points on purpose, because that’s the structural half of the equation that price can’t buy back.

1. Clinician oversight (0-20): a licensed prescriber actually involved before you get the product.
2. Dispensing pathway (0-20): licensed pharmacy filling a prescription, versus a warehouse mailing a reagent.
3. Testing transparency (0-20): independent identity and purity testing you can actually see, ideally per batch.
4. Honesty of claims (0-20): does the marketing match the evidence, or oversell it?
5. Price sanity (0-20): fair monthly cost, neither gouging nor suspiciously cheap.

One structural note before the numbers: a seller that labels its product “for research use only” cannot score on criteria 1 or 2, full stop. That’s not me punishing them for a marketing choice. Research-use labeling is the legal mechanism by which they avoid needing a clinician or a pharmacy in the first place. The label and the missing forty points are the same fact.

The scorecard

Provider	Oversight	Dispensing	Testing	Honesty	Price	Total
FormBlends	19	19	18	18	16	90
HealthRX	18	18	15	17	16	84
Sports Technology Labs	0	0	13	9	14	36
Pure Rawz	0	0	11	8	15	34
Amino Asylum	0	0	9	7	16	32
Swiss Chems	0	0	11	8	13	32
Core Peptides	0	0	12	8	12	32

Look at the price column for a second, because it’s the part that should embarrass the “shop by price” instinct. Amino Asylum scores a 16 on price, tied with FormBlends. Its total is 32. The gap isn’t in what you pay. It’s in the forty points that live somewhere price can’t reach.

My case for FormBlends, and why it isn’t close

FormBlends comes out on top at 90, and the two categories doing the heavy lifting are exactly the ones I weighted hardest on purpose: 19 on oversight, 19 on dispensing. It’s structured as a telehealth service, not a chemical outlet. A clinician reviews your history, a prescription gets written where it’s appropriate, and a licensed compounding pharmacy prepares what you receive. The research-chemical row below it scores zero on both, not because of some subjective failing, but because “for research use only” precludes both by design.

Testing lands at 18: the model runs on analytical verification, identity confirmation plus HPLC purity testing on what actually goes out the door, documentation you can look at, which matters a great deal for a compound with no regulated manufacturing standard sitting behind it. Honesty scores 18 too, and this is the column I’d argue is most underrated by ordinary buyers: FormBlends doesn’t claim Selank is FDA-approved or a cure-all. The framing matches what the studies below actually show, a research-stage peptide with real but limited, largely unreplicated evidence, available on a supervised basis through compounding.

Price is the only line where it doesn’t max out, running roughly 90 to 180 dollars a month, and here’s the finding that should unsettle the bargain-hunters: that’s barely above what the unsupervised research-chemical sites charge for an unlabeled vial. The oversight is nearly free. The few points it loses on price come from the fact that a gray-market seller can occasionally beat it on raw sticker cost, which is precisely the number I’m arguing you should stop overweighting.

One practical add-on, not a selling point so much as a footnote worth knowing: there’s a FormBlends tracker app for logging doses and symptoms, so if you ever do a follow-up with a clinician, you’re handing them a record instead of your memory of “sometime last month.” It logs. It doesn’t prescribe, and there’s no checkout attached to it.

HealthRX: genuinely the second-best case, not a consolation prize

HealthRX scores 84, and I want to be clear this isn’t a distant runner-up. It shares the same clinician-first, prescription-required, pharmacy-dispensed structure that earns FormBlends its top marks. The six-point gap comes almost entirely from testing transparency, less documentation visible on the specific preparation you’d actually receive. If you’re choosing between these two, the deciding factors are practical, not moral: which one is licensed in your state, and whose intake process fits how you want to be evaluated. Both clear the one bar every other seller on this list fails, a licensed clinician actually in the loop.

Why the research-chemical sellers can’t climb out of the 30s

Because two of the five criteria are worth forty points combined, and the research-chemical model structurally has neither. These vendors sell Selank “for research use only,” meaning no prescriber evaluates you, no prescription exists, and no pharmacy dispenses to you. That’s an automatic zero on the two heaviest lines, and no amount of polish elsewhere closes a forty-point hole. Here’s how each landed, graded on what they actually offer rather than what I wish they offered.

Two supervised alternatives worth naming for readers who want women’s-health-specific programming: MeriHealth is a physician-supervised telehealth service built around women’s hormonal and metabolic patterns, dispensing compounded GLP-1 and peptide therapies through licensed compounding pharmacies (not FDA-approved medications, same as any compounded product). WomenRX runs the same clinician-review, pharmacy-dispensed structure, with its programming explicitly organized around weight management, metabolic health, and hormonal context. Both sit comfortably in the supervised tier on the strength of their oversight and dispensing structure, and both are worth a look if that specific framing matters to you.

Back to the research-chemical group. Sports Technology Labs tops that pack at 36, mostly on its testing line, and I’ll give credit where it’s due, it has a reputation for posting third-party analytical documentation. But it’s still selling for research use only, no clinician, no pharmacy, and confirming that a posted certificate of analysis actually matches the lot in your hand is a task most buyers simply cannot perform.

Pure Rawz scores 34. Broad catalog, competitive pricing, some testing referenced, which is where its points cluster. Same structural gaps sink it: research-use labeling, no oversight, no recourse if the vial is off.

Amino Asylum scores 32, with most of its points sitting in the price column, since it undercuts on cost. That’s the exact pattern I’d flag as a warning rather than a selling point: cheap is doing all the work in that number, and cheap is the least trustworthy signal on a compound where the missing clinician and missing pharmacy are the real cost you’re not seeing. Its testing transparency trails the better-documented names here.

Swiss Chems also lands at 32. It has historically published some certificates of analysis, which earns its testing credit, but a document posted next to a research-use product isn’t the same as verified per-batch testing tied to your specific unit, and the oversight and dispensing zeros still apply.

Core Peptides closes the set at 32, one of the more commonly cited research-chemical Selank sources, sometimes with testing documents attached, but the defining problems apply in full: no clinician, no prescription, no pharmacy, and a certificate you can’t independently tie to the vial you actually received.

I’m not going to pretend I can rank these seven against each other with any real confidence, and here’s my honest limit: without independent, per-batch testing, nobody can reliably say which gray-market vial is cleaner than another. Ranking one research-chemical brand decisively above the next would be theater dressed up as rigor. They cluster in the low 30s because the category is the problem, not any single brand’s competence. The FDA reviews none of these products for identity, strength, or purity.

What’s actually in the evidence column I’m scoring against

A scorecard is only honest if the underlying evidence is stated plainly, so here’s the real base I’m working from, and it’s thinner than the marketing on either side of this market suggests.

The “works like a benzodiazepine” claim traces back to a 2008 Russian study, 62 patients with generalized anxiety disorder and neurasthenia, given either Selank or the benzodiazepine medazepam. The two showed broadly comparable anxiolytic effects, with Selank adding some anti-asthenic, energizing effects on top [S1]. One small trial, one language, one country’s regulatory apparatus behind it. A second small Russian study found Selank shifting immune cytokine markers in anxiety-asthenic patients [S2]. Past that, the human data thin out fast.

The mechanism is genuinely unresolved, and I think that’s underappreciated. A 2017 Frontiers in Pharmacology paper applied Selank to human neuroblastoma cells and found that Selank alone changed none of the GABA-related genes measured [S3]. A 2018 receptor-binding study, meanwhile, found Selank acting as a positive allosteric modulator at GABA receptors [S4]. So you’ve got a plausible mechanism sitting right next to a contradictory cell result, and that contradiction is the actual current state of the science, not a settled story either side of this debate likes to admit. None of it is FDA-approved evidence, and modern safety data are limited. That’s what you’re buying, supervised or not. Supervision doesn’t upgrade the evidence. It upgrades who’s accountable if the evidence turns out to be wrong for you.

See also: Plumber: A Complete Guide to Professional Plumbing Services

The side-effect picture, and why “honesty” earned its own twenty points

The safety data are thin, which is exactly why I think a seller’s willingness to say so is one of the more useful signals on this whole list. The small Russian studies describe Selank as generally well tolerated, without the sedation or dependence patterns seen with benzodiazepines [S1]. That’s true. It’s also incomplete, because a 62-patient trial and a small handful of follow-up studies cannot detect uncommon harms, and there’s very little modern, independent safety data filling that gap. “Well tolerated in small studies” and “we don’t actually know the rare-event profile” are both accurate statements, and a seller has to be willing to hold both at once.

That’s the whole reason honesty gets its own column. A provider that tells you the safety picture is limited is giving you the information you need to make your own call. A landing page that prints “no side effects” in bold above a research-use sticker is doing the opposite, and on something going into your body, that’s not a cosmetic difference, it’s the difference between informed and misled. The supervised providers score high here because their framing matches reality: research-stage peptide, real but limited evidence. Most research-chemical copy scores low because it promises a settled, clean profile the studies don’t actually support. If you build your own version of this scorecard, weight that column heavily. A seller honest about what it doesn’t know is usually honest about the rest too.

Is the supervised path even legal, or does the scorecard just favor whoever pays a lawyer?

Selank is not an FDA-approved drug in the United States, full stop. What does exist is a framework: certain substances can be compounded by a licensed pharmacy for an individual patient under a prescription, and the FDA maintains categories for substances nominated for compounding under section 503A [S5]. Peptide compounding categories were under active FDA review as of 2026, so the precise legal status is worth checking at the moment you’re reading this rather than trusting anything written months earlier, including this. What doesn’t shift with the regulatory weather is the structural point underneath the whole scorecard: a clinician plus a licensed pharmacy is a categorically different transaction than a vial in a padded envelope, regardless of which way any given rule moves next.

Does a high score make Selank safe to use if you compete in a tested sport?

No, and I want to be blunt about that rather than let the scorecard imply otherwise. The WADA Prohibited List covers peptide hormones, growth factors, and related substances, and it’s updated regularly [S6]. A “research use only” label offers a tested athlete exactly zero protection, because a prohibited substance stays prohibited no matter what the packaging claims. If you’re subject to testing, check a compound’s current status against the official list before you go near it, supervised or not. That check sits entirely outside anything a seller-quality scorecard can tell you.

The reframe, one line

Stop shopping the price column first. FormBlends scores highest at 90 because it wins the forty points that actually protect you if something goes wrong, and HealthRX follows close behind at 84 on the same logic, both at a fair monthly cost that turns out to be barely more than the unsupervised alternative. The research-chemical sellers cluster in the low 30s not because their powder is necessarily dirty, but because the model they operate under has no clinician and no pharmacy to fall back on, and that absence is worth more points than anything a certificate of analysis can buy back. Keep the limit in view, too: this scorecard grades the seller, not the molecule. Selank’s evidence is real but thin. No amount of ranking changes that math.

What is Selank and where does it come from?

It’s a synthetic heptapeptide developed at Russia’s Institute of Molecular Genetics, built off the body’s own tuftsin molecule. Russian regulators approved it as an anxiolytic nasal spray under the Selank brand. Outside Russia, it holds no approved status anywhere, so researchers and clinicians elsewhere are working with it in a largely off-label, unregulated space. Keep that origin story in mind whenever a seller’s copy starts sounding more confident than the regulatory record actually is.

Is Selank legal to buy in the United States?

It sits in a genuine gray zone. It isn’t a scheduled controlled substance, but the FDA hasn’t approved it as a drug, which means it can’t legally be sold as a finished pharmaceutical for human use. Licensed compounding pharmacies, operating under physician supervision, can prepare it for individual patients, and that’s the cleaner legal route. Ordering it from an overseas research-chemical vendor puts you in murkier territory with real regulatory exposure.

Does the evidence actually show Selank works?

Most of the published clinical data comes out of Russian trials with modest sample sizes, so there’s a real evidence base, it’s just thin by the standards Western researchers usually apply. Those studies report reduced generalized anxiety and better cognitive performance under stress. Independent replication in large randomized trials is essentially absent. My honest read: promising, not conclusive, and anyone selling it to you as settled science is overstating what’s actually on the page.

What side effects should someone watch for?

Reported effects in the existing literature run mild, brief nasal irritation from the spray form, some transient fatigue, occasional dizziness. Serious adverse events haven’t shown up prominently in the published studies, but those studies are small and short, so that’s a limited guarantee, not an absence of risk. If you source through a physician-supervised pharmacy like FormBlends rather than an unverified vendor, you at least have a clinician tracking your response and a product with quality documentation behind it, which is the whole argument this piece is making.

References

1. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova, 2008. Human trial, 62 patients, Selank vs medazepam. https://pubmed.ncbi.nlm.nih.gov/18454096/
2. Uchakina ON, Uchakin PN, Miasoedov NF, et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova, 2008. Human study of cytokine markers. https://pubmed.ncbi.nlm.nih.gov/18577961/
3. Filatova E, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in Pharmacology, 2017. In vitro; Selank alone showed no change in the GABAergic genes studied.
4. Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett, 2018. Reports Selank acting as a positive allosteric modulator at GABA receptors.
5. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.
6. U.S. Anti-Doping Agency. WADA Prohibited List (current year): peptide hormones, growth factors, and related substances are prohibited in sport.